Clinical Efficacy and Therapeutic Outcomes of CAMZYOS

CAMZYOS has demonstrated efficacy in improving exercise capacity, reducing LVOT gradients, and alleviating symptoms in adults with symptomatic NYHA class II-III obstructive hypertrophic cardiomyopathy. Clinical trials showed a higher proportion of patients achieving meaningful improvements in peak oxygen consumption and NYHA class compared to placebo. Secondary benefits include reductions in NT-proBNP and cardiac troponin I, as well as improvements in health status and quality of life measures. The therapeutic effect in non-obstructive HCM or other populations is not specified in the description.